



## SUPPORTING INNOVATION AND TECHNOLOGY TRANSFER IN ONCOLOGY

### ADC 2.0

### NEW GENERATION OF ANTIBODY-DRUG CONJUGATES WITH AN ENHANCED THERAPEUTIC EFFICACY



#### CONTEXT & BACKGROUND

Antibody-drug conjugates (ADCs) is the most promising class of anticancer drugs that combine high specificity of therapeutic antibodies with high potency of small molecular drugs. They consist of three elements: an antibody, a cytotoxic drug and a linker that binds (conjugates) two fragments together. The conjugation technology is of crucial importance, since it determines the site of drug attachment, the drug-to-antibody ratio (DAR) and the DAR distribution. All these parameters define pharmacokinetics and toxicity profile of ADCs. Syndivia combines a strong portfolio of efficient conjugation technologies with the know-how in antibody-drug conjugation, analysis of ADCs (DAR, DAR distribution, attachment site) and evaluation of their stability (drug release mechanism) and biological activity. An enhanced efficiency of our ADCs was successfully demonstrated in vitro and in vivo.



#### INNOVATIVE COMPONENT & TECHNOLOGY

New conjugation technologies allowing for the preparation of Antibody-Drug Conjugates with an enhanced efficiency and an improved safety profile

#### SCOPE

Targeted therapies  
- discovery and  
development

#### KEYWORDS

Cancer therapeutics,  
Antibody-Drug  
Conjugates,  
Immunoconjugates,  
breast cancer, pancreatic  
cancer



#### OBJECTIVES

The ultimate goal of Syndivia is to bring to the market a new generation of Antibody-Drug Conjugates with an enhanced therapeutic efficacy and better safety profile.

With a strong portfolio of validated technologies for the preparation of next-generation ADCs, the current objective of Syndivia is to establish partnerships with pharmaceutical and biotechnology companies for the development of new ADCs. Preclinical data from our own drug candidates and comparison with commercial ADCs serve as support for validation of our technology.



## DEVELOPMENT & MATURATION STAGE

An enhanced therapeutic efficiency of Syndivia's Antibody-Drug Conjugates was successfully demonstrated in vitro and in vivo. A partnered product pipeline of 4 targeted cancer therapeutics is currently under development. The product pipeline includes:

1. SDV1001 - a targeted cytotoxic agent fully owned by Syndivia
2. SDV2101 - an internalising ADC co-developed with a biotech company
3. SDV2102 - a highly innovative non-internalising ADC co-developed with a biotech company
4. SDV2201 - an ADC developed in collaboration with a big pharma company



## STRENGTHS & COMPETITIVE ADVANTAGES

Syndivia has a strong portfolio of conjugation technologies allowing for the preparation of safer and more efficient AntibodyDrug Conjugates for cancer treatment. New technologies, a strong and experienced team and a broad network of partners are the pillars of Syndivia's success



## INDUSTRIAL APPLICATIONS & OPPORTUNITIES

- Co-development of next-generation Antibody-Drug Conjugates for cancer treatment.
- Validation of new antibodies in the ADC approach.
- Validation of new cytotoxic payloads in the ADC approach.

